Amplify Weight Loss Drug & Treatment ETF's Amplify Weight Loss Drug & Treatment ETF has disclosed 27 total holdings in their latest N-PORT filing with the SEC for the
portfolio date of 2024-06-30. The current portfolio value is calculated to be $3.00 Mil, only including common equities, preferred
equities, ETFs, options and warrants for equities. The turnover rate is 0%.
Amplify Weight Loss Drug & Treatment ETF's
Total Assets is $3.12 Mil , Total Liabilities is $1,200.00 , Net Assets is $3.12 Mil.
In Amplify Weight Loss Drug & Treatment ETF's current portfolio as of 2024-06-30, the top 5 holdings are
Eli Lilly and Co (LLY), Novo Nordisk AS (NVO), AstraZeneca PLC (AZN), Amgen Inc (AMGN) and FUJIFILM Holdings Corp (TSE:4901),
not including call and put options.
Amplify Weight Loss Drug & Treatment ETF did not buy any new stocks in the current portfolio.
Please visit the "Current Portfolio" tab to see the ETF's current and past N-PORT holdings for Amplify Weight Loss Drug & Treatment ETF, as well as holding map,
valuations for each stock, which positions are undervalued, have low PE Ratios, are considered high quality and recently traded at 52-week lows, etc.
Please visit the "Stock Picks" tab to see the ETF's latest trades and stock picks for Amplify Weight Loss Drug & Treatment ETF, which include data from form N-PORT.
Please visit the "Summary" page to see the top 10 holdings, recent stock picks, performance, sector / industry breakdown details, as well as past holding history summary for Amplify Weight Loss Drug & Treatment ETF.